Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 15/20 | 0.44 |
| ▸ | MAOA | P21397 | 14/20 | 0.44 |
| ▸ | MAOB | P27338 | 14/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4558684 | 0.76 | KDM1A (0.42) | KDM1AMAOAMAOB | |
| SCHEMBL13556691 | 0.72 | KDM1A (0.53) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL14045495 | 0.72 | KDM1A (0.53) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL15766923 | 0.72 | KDM1A (0.53) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL15541000 | 0.72 | KDM1A (0.53) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL3530324 | 0.72 | KDM1A (0.53) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL11519546 | 0.71 | KDM1A (0.44) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL16880856 | 0.71 | KDM1A (0.37) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL28885401 | 0.71 | KDM1A (0.41) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL5435422 | 0.71 | MAPK1 (0.50) | KDM1AMAOAMAOBMAPK1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112867705-B | Opioid receptor modulators and products and methods related thereto | 埃皮欧黛公司 | 2024-08-20 | — | — | CN | disclosed |
| EP-3774722-B1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20210163402-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. | 2021-06-03 | — | — | US | disclosed |
| CN-112867705-A | Opioid receptor modulators and products and methods related thereto | 埃皮欧黛公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20210147343-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. | 2021-05-20 | — | — | US | disclosed |
| EP-3774722-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | Epiodyne, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019195634-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163402-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | OPRM1, OPRD1, OPRK1 | KDM1A 2305/4885MAOA 1124/4885MAOB 774/4885 |
| US-20210147343-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | OPRM1, OPRD1, OPRK1 | KDM1A 2140/4885MAOA 1168/4885MAOB 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.